[Clinical analysis of combination therapy for 252 patients of lung cancer with brain metastasis].
OBJECTIVE
To evaluate the efficacy of combination therapy and prognostic factors for lung cancer patients with brain metastasis.


METHODS
The survival time and survival rates with various therapeutic methods were analyzed retrospectively in 252 patients with brain metastasis.


RESULTS
The median survival time and 1, 2 year survival rates in surgery and X-knife plus radio-chemotherapy group and combination therapy of radiotherapy with chemotherapy were significantly longer than radio-chemotherapy alone group (P < 0.01 and P < 0.05); the pathological type of lung cancer did not affect the survival time and survival rate (P > 0.05); the survival time and survival rate of single brain metastasis (median survival time was 8.5 months 1, 2 year survival rates were 35% and 11% respectively) and non-extrabrain metastasis (8.5 months, 29%, 8%) were much longer than multiple brain metastasis and extrabrain metastasis (P < 0.01); the 1 year survival rate of older patients(> or = 50 years, 29%) were significantly higher than younger ones (< 50 years, 15%) (P < 0.05).


CONCLUSIONS
Combination therapy of surgery and X-knife plus radio-chemotherapy are better than radio-chemotherapy alone for brain metastasis of lung cancer, severity of metastasis and patients' age are the prognostic factors.
Zhang
S
S
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149.
Yang
X
X
Zhao
A
A
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome